David R. Plowchalk

Houston Methodist · US

Area of research

Pharmacology · Public Health, Environmental and Occupational Health

Research interest

Research interests include Placebo, PCSK9, Dose-ranging study, Medicine, and Kexin.

h-index

—

citations

168

works

NIH funding

—

primary concept

—

✉ Find email ↗

Recent publications

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia

The American Journal of Cardiology 2015cited by 168position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nitin Kaila · Houston Methodist1 papers (2015–2015)Kevin Sweeney · Houston Methodist1 papers (2015–2015)Anne Cropp · Houston Methodist1 papers (2015–2015)Joel Neutel · Lake County1 papers (2015–2015)William Duggan · Houston Methodist1 papers (2015–2015)John Vincent · Houston Methodist1 papers (2015–2015)— · 1 papers (2015–2015)Christie M. Ballantyne · New York University1 papers (2015–2015)Harold Bays · Louisville Metabolic and Atherosclerosis Research Center1 papers (2015–2015)